Chardan Capital Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) had its price objective raised by investment analysts at Chardan Capital from $31.00 to $37.00 in a report issued on Thursday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 93.41% from the company’s previous close.

A number of other brokerages also recently commented on QURE. Wolfe Research assumed coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $15.00 to $60.00 in a report on Monday, March 9th. Stifel Nicolaus set a $14.00 price target on shares of uniQure in a research note on Monday, March 2nd. Leerink Partners reissued an “outperform” rating and set a $35.00 price target on shares of uniQure in a report on Monday, March 2nd. Finally, Barclays lowered their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.33.

uniQure Trading Down 4.1%

NASDAQ:QURE opened at $19.13 on Thursday. uniQure has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock’s 50 day simple moving average is $16.75 and its 200-day simple moving average is $26.01. The firm has a market cap of $1.21 billion, a P/E ratio of -5.54 and a beta of 0.75.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. Equities analysts anticipate that uniQure will post -3.6 EPS for the current year.

Insider Activity

In other news, insider Jeannette Potts sold 3,412 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares in the company, valued at $1,254,655.98. This trade represents a 2.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christian Klemt sold 12,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the sale, the chief financial officer directly owned 226,581 shares in the company, valued at approximately $2,052,823.86. This represents a 5.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 49,396 shares of company stock worth $722,734 in the last 90 days. 4.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently modified their holdings of the company. Avoro Capital Advisors LLC raised its holdings in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Aberdeen Group plc grew its holdings in uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the last quarter. State Street Corp grew its holdings in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of uniQure by 23.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after buying an additional 383,066 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported a successful pre-submission meeting with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for AMT?130 and said it expects to submit a U.K. Marketing Authorization Application in Q3 2026 — a clear pathway to pursue approval outside the U.S. and a major near-term regulatory milestone. uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130
• Positive Sentiment: Market coverage and outlets reported an immediate positive market reaction to the U.K. update (coverage noted intraday gains), reflecting investor optimism that a U.K. approval route could salvage commercial prospects after prior U.S. regulatory friction. QURE stock just shot up 8% – MSN
• Positive Sentiment: Analyst support: Chardan Capital raised its price target from $31 to $37 and reiterated a “buy” rating, increasing upside expectations and likely supporting bullish sentiment. Benzinga Coverage of Chardan PT Raise
• Neutral Sentiment: Corporate calendar: uniQure is expected to announce quarterly earnings on Tuesday — this event could amplify short-term volatility as investors reassess guidance, cash burn and program timelines. Earnings Date Notice
• Negative Sentiment: Regulatory risk remains material: coverage highlights prior disagreements with the U.S. FDA over AMT?130; while the U.K. route is promising, successful MHRA interactions don’t eliminate the possibility of later setbacks or additional data requirements. Biospace on FDA Quarrel and UK Strategy
• Negative Sentiment: Fundamental risks: uniQure remains loss-making with limited current revenue, making its valuation highly sensitive to regulatory and commercial outcomes for AMT?130 and other pipeline assets. (Refer to recent financials for full detail.)

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.